Status:
RECRUITING
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
Atrium Health Levine Cancer Institute
Swim Across America
Conditions:
Leukemia, Myeloid, Acute
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Detailed Description
This is a prospective pilot study of the association of SNPs and venetoclax levels with toxicity and response to azacitidine plus venetoclax (Aza/Ven) as well as pharmacogenomics and venetoclax levels...
Eligibility Criteria
Inclusion
- Written informed consent and HIPAA authorization for release of personal health information.
- Age ≥ 18 years of age at the time of enrollment
- Confirmed diagnosis of AML
- Planned initial treatment with azacitidine and venetoclax
- Ability to read and understand the English and/or Spanish language
- As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Exclusion
- None
Key Trial Info
Start Date :
April 9 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06580106
Start Date
April 9 2025
End Date
January 1 2030
Last Update
July 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
2
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157